GITR Antibodies Modulate Treg Suppression for Anti-Tumor Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increased presence of regulatory T-cells (Tregs) in cancer patients suppresses effector T-cell activity, leading to reduced anti-tumor immune responses, necessitating agents that can modulate GITR activity to enhance effector T-cell function and anti-tumor immunity.
Innovation Solution
Development of humanized monoclonal antibodies specifically binding to the glucocorticoid-induced tumor necrosis factor receptor (GITR), which interrupt the GITR ligand's binding, thereby reducing Treg suppressive function and increasing effector T-cell activity and antigen-specific immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Tregs are present in increased amounts in cancer patients, then immune homeostasis is maintained, but effector T-cell activity is suppressed and anti-tumor immune responses are reduced
Solution Approach 1:
The patent applies local quality by selectively modulating GITR activity in different cell types. The antibody specifically targets GITR on Tregs to reduce their suppressive function, while preserving or enhancing GITR-mediated activation of effector T cells. This differential modulation allows maintenance of immune homeostasis in certain contexts while boosting anti-tumor immunity where needed.
Solution Approach 2:
The patent employs parameter changes by altering the functional state of GITR through antibody binding. The anti-GITR antibody changes the receptor's ligand-binding properties and downstream signaling parameters, transforming GITR from a purely suppressive receptor on Tregs to a receptor that can be selectively activated or blocked depending on the cellular context and antibody concentration.
2Productivity
If GITR ligand binding is increased to enhance effector T-cell activity, then anti-tumor immune response is improved, but Treg suppressive function is also enhanced
Solution Approach 1:
The patent applies inversion by using an antibody that binds to GITR in a manner that inverts the normal ligand-induced signaling outcome. Instead of GITR-L binding to activate or suppress depending on cell type, the antibody binds GITR and induces the opposite effect: suppressing Treg function while activating effector T cells. This inverts the harmful suppressive action into a beneficial therapeutic effect.
Solution Approach 2:
The patent introduces an intermediary (the anti-GITR antibody) that mediates the interaction between GITR and its ligand. The antibody serves as a third-party mediator that binds GITR and alters its signaling properties, preventing harmful Treg-mediated suppression while promoting beneficial effector T cell activation, thereby resolving the contradiction without requiring direct modification of the GITR-LIGAND interaction itself.
3Stability of the object's composition
If conventional T cells are suppressed by Tregs, then immune tolerance is maintained, but anti-tumor immunity is reduced
Solution Approach 1:
The patent applies local quality by selectively reversing Treg suppression of conventional T cells through GITR antibody binding. The antibody locally modifies the GITR receptor on Tregs to reduce their suppressive output, thereby restoring conventional T cell activity in anti-tumor contexts while preserving immune tolerance in non-pathogenic contexts through selective cellular targeting.
Data Source
AI summary
The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.